Core Insights - BioStem Technologies, Inc. has appointed Brandon Poe as Chief Financial Officer, marking a significant leadership change during a period of growth and innovation for the company [1][2] - The company is recognized for its innovative wound care technologies and aims to leverage its BioREtain® platform to accelerate growth and expand market presence [3] Company Overview - BioStem Technologies focuses on the development, manufacturing, and commercialization of placental-derived products for advanced wound care [1] - The company utilizes its proprietary BioREtain® processing method, which is designed to maintain growth factors and preserve tissue structure [3] - BioStem's quality management system has been accredited by the American Association of Tissue Banks and adheres to current Good Tissue Practices and Good Manufacturing Processes [3] Leadership Background - Brandon Poe brings over 25 years of experience in finance within the healthcare and life sciences sectors, having previously served as CFO at Midi Health, Inc. and Jumpcode Genomics, Inc. [2] - His experience at Illumina, Inc. included multiple senior finance roles, enhancing his capability to contribute to BioStem's strategic goals [2] Strategic Goals - The company aims to expand into new markets and advance its plans for a Nasdaq uplisting, indicating a focus on long-term growth ambitions [2] - Brandon Poe expressed enthusiasm about driving value for shareholders and executing the company's strategy during this pivotal stage [3]

Core Insights - Adia Nutrition Inc. has opened its first licensed clinic, Adia Med of San Antonio, under a strategic license agreement, led by Dr. Michele DeLeon [1][2] - The clinic aims to expand access to innovative regenerative therapies in the U.S. and will offer FDA-registered products, including AdiaVita and AdiaLink [1][2] - A clinical study focusing on regenerative therapies for autism will be conducted in collaboration with Adia Med of Winter Park, highlighting the company's commitment to transformative healthcare solutions [2] Company Overview - Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) focused on revolutionizing healthcare and supplementation through two main divisions: a supplement division and a medical division specializing in stem cell therapies [3] - The medical division emphasizes treatments involving Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) [3] - The company is dedicated to empowering individuals by addressing nutritional needs and providing groundbreaking medical treatments [3]

Core Viewpoint - BioStem Technologies Inc. will release its first quarter 2025 financial results on May 12, 2025, and will host a conference call and webcast to discuss the results [1][2]. Company Overview - BioStem Technologies is a MedTech company focused on developing, manufacturing, and commercializing placental-derived biologics for advanced wound care [1][4]. - The company utilizes its proprietary BioREtain processing method to maintain growth factors and preserve tissue structure in its products [4]. - BioStem's quality management system has been accredited by the American Association of Tissue Banks (AATB) and adheres to current Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP) [4]. Upcoming Events - The conference call and webcast will feature an overview of the quarter from CEO Jason Matuszewski and CFO Michael Fortunato [2]. - Interested parties can register for the event and follow the company on social media for updates [3]. Contact Information - BioStem Technologies can be contacted via phone at 954-380-8342 or through their website [7]. - Investor relations inquiries can be directed to Adam Holdsworth at adam@holdsworthco.com [7].